English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Pyruvate carboxylase deficiency type A and type C: Characterization of 5 novel pathogenic variants in PC and analysis of the genotype-phenotype correlation.

MPS-Authors
/persons/resource/persons32617

Gapsys,  V.
Research Group of Computational Biomolecular Dynamics, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons14970

de Groot,  B.
Research Group of Computational Biomolecular Dynamics, MPI for biophysical chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

3034191.pdf
(Preprint), 474KB

Supplementary Material (public)

3034191_Suppl_1.pdf
(Supplementary material), 247KB

3034191_Suppl_2.mp4
(Supplementary material), 52MB

3034191_Suppl_3.pdf
(Supplementary material), 188KB

Citation

Coci, E. G., Gapsys, V., Shur, N., Shin‐Podskarbi, Y., de Groot, B., Miller, K., et al. (2019). Pyruvate carboxylase deficiency type A and type C: Characterization of 5 novel pathogenic variants in PC and analysis of the genotype-phenotype correlation. Human Mutation, (in press). doi:10.1002/humu.23742.


Cite as: https://hdl.handle.net/21.11116/0000-0003-3282-1
Abstract
Pyruvate carboxylase deficiency (PCD) is caused by bi-allelic mutations of the PC gene. The reported clinical spectrum includes a neonatal form with early death (type B), an infantile fatal form (type A), and an late onset form with isolated mild intellectual delay (type C). Apart from homozygous stop-codon mutations leading to type B PCD, a genotype-phenotype correlation has not otherwise been discernible. Indeed, patients harboring bi-allelic heterozygous variants leading to PC activity near zero can present either with a fatal infantile type A or with a benign late onset type C form. In this study, we analyzed six novel patients with type A (three) and type C (three) PCD, and compared them with previously reported cases. Firstly, we observed that type C PCD is not associated to homozygous variants in PC. In-silico modeling was used to map former and novel variants associated to type A and C PCD, and to predict their potential effects on the enzyme structure and function. We found that variants lead to type A or type C phenotype based on the destabilization between the two major enzyme conformers. In general, our study on novel and previously reported patients improves the overall understanding on type A and C PCD.